Contract Doctor Producer Catalyzed to Buy Paragon Bioservices in $ 1.2 Billion Deal


Contract drug manufacturer Catalent Inc. agreed to buy tightly kept Paragon Bioservices Inc. for $ 1.2 billion, according to the people familiar with the case, the latest deal in the emerging gene therapy market.

The all-cash deal, which is expected to be announced on Monday morning, will help Catalent expand its gene therapy production capability, the people said. The transaction is expected to close in the second quarter.

Source link

Back to top button